What impact do Revlimid® (lenalidomide) and Pomalyst® (pomalidomide) have on the bone marrow?

(3:10)

What is lenalidomide and when is it used for MDS?

(3:19)

Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma

(1:39)

Dr. Orlowski on Bortezomib Added to Lenalidomide and Dexamethasone for Multiple Myeloma

(1:32)

Real world data of ixazomib in combination with lenalidomide and dexamethasome

(1:49)

Dr. Bahlis on Daratumumab Plus Lenalidomide and Dexamethasone in Multiple Myeloma

(1:17)

Biomarkers to predict outcomes in patients with myeloma treated with lenalidomide and dexamethasone

(2:24)

Approaches taken for patients with multiple myeloma with resistance to lenalidomide and bortezomib

(1:39)

Lenalidomide and azacitidine with radiotherapy for patients with plasmacytomas

(3:53)

The safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in NDMM

(50)

Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL

(5:12)

Lenalidomide and Ixazomib: a successful amyloidosis treatment combination?

(4:28)

Dr. Schuster on Long-Term Outcomes of Lenalidomide and Rituximab in MCL

(2:10)

Daratumumab Combined With Carfilzomib, Lenalidomide, and Dexamethasone in Multiple Myeloma

(3:15)

Relapsed follicular lymphoma: hope from a non-chemotherapy regimen of lenalidomide and obinutuzumab

(1:53)

IMW 2011: Lenalidomide and continuous therapy for multiple myeloma

(18:11)

Tazemetostat in combination with lenalidomide and rituximab for R/R follicular lymphoma

(1:48)

Management of FL relapsed or progressed after frontline lenalidomide and rituximab

(1:38)

The association between prior exposure to lenalidomide and TP53-mutated AML/MDS

(3:39)

Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma

(4:5)